AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24160184 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher professional development (6 days) aimed at improving expressive and receptive oral language skills and early literacy; included school-based continuing contact and completion of a postgraduate unit on early language and literacy.
Number of subjects: 1254
Study 24160184 — intervention group
Group type: COMPARATOR
Intervention: Standard teaching according to state auspiced curriculum guidelines (control arm).
Number of subjects: 1254
Study 22677258 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD106 50 μg
Number of subjects: 58
Study 22677258 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD106 150 μg
Number of subjects: 58
Study 22677258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 22677258 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD106 (both dosages)
Number of subjects: 58
Study 21125811 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlortalidone (12.5 mg/day)
Number of subjects: 40
Study 21125811 — intervention group
Group type: COMPARATOR
Intervention: Trichlormethiazide (1 mg/day)
Number of subjects: 40
Study 21125811 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlortalidone
Number of subjects: 40
Study 21125811 — intervention group
Group type: COMPARATOR
Intervention: Trichlormethiazide
Number of subjects: 40
Study 17935533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relationship enhancement program
Number of subjects: 0
Study 15802115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (counseling on stopping smoking, low-calorie diet, physical exercise)
Number of subjects: 436
Study 15802115 — intervention group
Group type: COMPARATOR
Intervention: Customary treatments (control group)
Number of subjects: 436
Study 15802115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 436
Study 16882959 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interview with a health care provider (physician or nurse)
Number of subjects: 2602
Study 16882959 — intervention group
Group type: EXPERIMENTAL
Intervention: Written self-completed questionnaire (WAST)
Number of subjects: 2602
Study 16882959 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based self-completed questionnaire
Number of subjects: 2602
Study 16882959 — intervention group
Group type: EXPERIMENTAL
Intervention: Written format (WAST)
Number of subjects: 2602
Study 16882959 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner Violence Screen (PVS)
Number of subjects: 2602
Study 16882959 — intervention group
Group type: EXPERIMENTAL
Intervention: Woman Abuse Screening Tool (WAST)
Number of subjects: 2602
Study 16882959 — intervention group
Group type: EXPERIMENTAL
Intervention: Written WAST vs other combinations
Number of subjects: 2602
Study 11763911 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil-containing dentifrice (EO)
Number of subjects: 321
Study 11763911 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (without essential oils)
Number of subjects: 321
Study 8840945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin tablets 500,000 units four times a day
Number of subjects: 397
Study 8840945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nystatin)
Number of subjects: 397
Study 8840945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 397
Study 1515389 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar block
Number of subjects: 300
Study 1515389 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar block
Number of subjects: 300
Study 1515389 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients (less than 65 years)
Number of subjects: 300
Study 1515389 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients
Number of subjects: 300
Study 6434423 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids infusion (group 1)
Number of subjects: 0
Study 6434423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined essential and non-essential amino acids infusion (group 2)
Number of subjects: 0
Study 6434423 — intervention group
Group type: COMPARATOR
Intervention: Routine laboratory data and protein metabolism parameters (both groups)
Number of subjects: 0
Study 30305345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla‐300 (0.35 ± 0.08 units · kg‐1)
Number of subjects: 18
Study 30305345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla‐300
Number of subjects: 18
Study 29154168 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy plus a web‐based depression program ("deprexis")
Number of subjects: 98
Study 29154168 — intervention group
Group type: COMPARATOR
Intervention: Regular psychotherapy
Number of subjects: 98
Study 27750364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic unloader brace and conventional treatment
Number of subjects: 36
Study 27750364 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 36
Study 24417765 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 61
Study 24417765 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 61
Study 24417765 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal P-wave duration
Number of subjects: 61
Study 24417765 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (aIAB presence)
Number of subjects: 61
Study 24417765 — intervention group
Group type: COMPARATOR
Intervention: Drug used for cardioversion (Propafenone vs Vernakalant)
Number of subjects: 61
Study 22822190 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 61
Study 22822190 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training after second session
Number of subjects: 61
Study 22822190 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 61
Study 22822190 — intervention group
Group type: COMPARATOR
Intervention: Control training after second session
Number of subjects: 61
Study 19997723 — intervention group
Group type: EXPERIMENTAL
Intervention: High diuresis (Group D) - pressure infusion of approximately 1 L of Ringer acetate solution and 20 mg of furosemide during a 30-40 min treatment session.
Number of subjects: 125
Study 19997723 — intervention group
Group type: COMPARATOR
Intervention: Normal diuresis (Group 0) - no bladder catheter.
Number of subjects: 125
Study 19012818 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day lisdexamfetamine
Number of subjects: 420
Study 19012818 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day lisdexamfetamine
Number of subjects: 420
Study 19012818 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg/day lisdexamfetamine
Number of subjects: 420
Study 19012818 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 420
Study 15867832 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education program (Open Airways) followed by 5 monthly visits with a nurse practitioner
Number of subjects: 52
Study 15867832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 12790313 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based (EB) booklet
Number of subjects: 214
Study 12790313 — intervention group
Group type: COMPARATOR
Intervention: Conventional information
Number of subjects: 214
Study 12790313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 214
Study 10649933 — intervention group
Group type: COMPARATOR
Intervention: Compoglass (C)
Number of subjects: 31
Study 10649933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC (F)
Number of subjects: 31
Study 8907141 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive intrasurgical suggestion directed towards reducing pain
Number of subjects: 0
Study 8907141 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving information about pain without suggestion content
Number of subjects: 0
Study 2063854 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (50 U/kg IV three times a week, increased by 25 U/kg every 4 weeks)
Number of subjects: 20
Study 2063854 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (150 to 300 U/kg/week)
Number of subjects: 20
Study 2063854 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment (control group)
Number of subjects: 20
Study 30879077 — intervention group
Group type: EXPERIMENTAL
Intervention: 'overload' message with 2/2 threat‐to‐efficacy ratio
Number of subjects: 242
Study 30879077 — intervention group
Group type: COMPARATOR
Intervention: 'standard' message with 1/1 threat‐to‐efficacy ratio
Number of subjects: 242
Study 30879077 — intervention group
Group type: EXPERIMENTAL
Intervention: High efficacy information
Number of subjects: 242
Study 31547503 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin-rich antioxidant juice (AJ), dosage: 240 mL twice-a-day for nine days
Number of subjects: 30
Study 31547503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA), dosage: 240 mL twice-a-day for nine days
Number of subjects: 30
Study 31547503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 30
Study 31547503 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin-rich antioxidant juice (AJ)
Number of subjects: 30
Study 28762617 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended full-dose betrixaban (80 mg once daily)
Number of subjects: 28227
Study 28762617 — intervention group
Group type: COMPARATOR
Intervention: Standard-duration enoxaparin
Number of subjects: 28227
Study 28762617 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 28227
Study 28762617 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 28227
Study 28762617 — intervention group
Group type: COMPARATOR
Intervention: Reduced-dose betrixaban
Number of subjects: 28227
Study 25357120 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trial (40 × 6 s maximal cycle sprints)
Number of subjects: 9
Study 25357120 — intervention group
Group type: COMPARATOR
Intervention: Control trial (inactive)
Number of subjects: 9
Study 25357120 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trial
Number of subjects: 9
Study 23838844 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 0
Study 23838844 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 0
Study 23838844 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 0
Study 21268098 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal distension (150 ml of normal saline)
Number of subjects: 30
Study 21268098 — intervention group
Group type: COMPARATOR
Intervention: Rectum undistended
Number of subjects: 30
Study 21268098 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal distension
Number of subjects: 30
Study 19116960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 16
Study 19116960 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 16545434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 34
Study 16545434 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 34
Study 15848978 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial chlorhexidine/thymol-containing varnish
Number of subjects: 32
Study 15848978 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 32
Study 11561502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold compression dressing (Cryo/Cuff, Aircast, UK)
Number of subjects: 60
Study 11561502 — intervention group
Group type: COMPARATOR
Intervention: Modified Robert Jones bandage
Number of subjects: 60
Study 9782139 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative administration of two injections of a depot formulation of leuprolide acetate 28 days apart
Number of subjects: 67
Study 9782139 — intervention group
Group type: COMPARATOR
Intervention: Direct surgery
Number of subjects: 67
Study 8164940 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum Papanicolaou smear at 4 weeks
Number of subjects: 184
Study 8164940 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum Papanicolaou smear at 6 weeks
Number of subjects: 184
Study 8164940 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum Papanicolaou smear at 8 weeks
Number of subjects: 184
Study 8164940 — intervention group
Group type: COMPARATOR
Intervention: Repeat smear done 3 months after postpartum examination
Number of subjects: 184
Study 3059587 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur Sprinkle
Number of subjects: 14
Study 3059587 — intervention group
Group type: EXPERIMENTAL
Intervention: Slo-bid
Number of subjects: 14
Study 3059587 — intervention group
Group type: COMPARATOR
Intervention: Slo-Phyllin Gyrocaps (reference)
Number of subjects: 14
Study 31295916 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal lipid‐based nutrient supplement (LNS)
Number of subjects: 966
Study 27408987 — intervention group
Group type: EXPERIMENTAL
Intervention: Mushroom blend containing Cordyceps militaris (4 g·d‐1)
Number of subjects: 28
Study 27408987 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (PL)
Number of subjects: 28
Study 26009024 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of cotrimoxazole (CTX) prophylaxis
Number of subjects: 0
Study 26009024 — intervention group
Group type: COMPARATOR
Intervention: Continuation of cotrimoxazole (CTX) prophylaxis
Number of subjects: 0
Study 23482526 — intervention group
Group type: EXPERIMENTAL
Intervention: VenaSeal™
Number of subjects: 0
Study 23482526 — intervention group
Group type: COMPARATOR
Intervention: Covidien ClosureFast™
Number of subjects: 0
Study 21298654 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 82
Study 21298654 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 5 mg/ezetimibe 5 mg
Number of subjects: 82
Study 19026531 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (thiopental 4 mg/kg, succinylcholine 1-1.5 mg/kg, 1% end-tidal concentration of sevoflurane in nitrous oxide and 50% oxygen)
Number of subjects: 35
Study 19026531 — intervention group
Group type: COMPARATOR
Intervention: Neuraxial anesthesia (intrathecal 0.5% levobupivacaine 1.8-2.2 mL and epidural fentanyl 1 microg/kg)
Number of subjects: 35
Study 19026531 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 35
Study 19026531 — intervention group
Group type: COMPARATOR
Intervention: Neuraxial anesthesia
Number of subjects: 35
Study 16883221 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg b.i.d for 90 days)
Number of subjects: 44
Study 16883221 — intervention group
Group type: COMPARATOR
Intervention: Control (no gemfibrozil)
Number of subjects: 44
Study 15536776 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (1500 mg weekly in divided doses)
Number of subjects: 46
Study 11421840 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/ml (7.5%) hypertonic saline (HS) administered at 1.6 ml/kg
Number of subjects: 40
Study 11421840 — intervention group
Group type: COMPARATOR
Intervention: 9 mg/ml normal saline administered at 13 ml/kg
Number of subjects: 40
Study 11421840 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/ml (7.5%) hypertonic saline (HS)
Number of subjects: 40
Study 11421840 — intervention group
Group type: COMPARATOR
Intervention: 9 mg/ml normal saline
Number of subjects: 40
Study 9010482 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole resting saliva
Number of subjects: 8
Study 9010482 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole saliva during chewing-stimulation
Number of subjects: 8
Study 9010482 — intervention group
Group type: COMPARATOR
Intervention: Resting saliva
Number of subjects: 8
Study 9010482 — intervention group
Group type: EXPERIMENTAL
Intervention: Parotid saliva with increased secretion rates
Number of subjects: 8
Study 9010482 — intervention group
Group type: EXPERIMENTAL
Intervention: Parotid saliva over time with increased secretion rates
Number of subjects: 8
Study 8515969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenses with varying back optic zone radius (BOZR) from 8.20 to 9.00 mm
Number of subjects: 20
Study 8515969 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocurve lenses
Number of subjects: 20
Study 8515969 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicurve and aspheric lenses
Number of subjects: 20
Study 8515969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenses with edge thickness varying from 0.12 to 0.24 mm
Number of subjects: 20
Study 8515969 — intervention group
Group type: EXPERIMENTAL
Intervention: Plus power lenses (+1.00 to -6.00 D)
Number of subjects: 20
Study 2894715 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (I/C group)
Number of subjects: 143
Study 2894715 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime combined with metronidazole and cloxacillin (CX/M/CL group)
Number of subjects: 143
Study 30528419 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cholesterol-lowering nutraceutical containing artichoke dry extract and berberine
Number of subjects: 0
Study 30528419 — intervention group
Group type: COMPARATOR
Intervention: Standardized control diet
Number of subjects: 0
Study 28449590 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom™ G4 Platinum CGM System®
Number of subjects: 116
Study 28449590 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring blood glucose (SMBG)
Number of subjects: 116
Study 25629793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide and isotonic nasal saline for 2 weeks
Number of subjects: 60
Study 25629793 — intervention group
Group type: COMPARATOR
Intervention: Isotonic nasal saline for 2 weeks
Number of subjects: 60
Study 23522927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Self-Management (PSM) program
Number of subjects: 141
Study 23522927 — intervention group
Group type: COMPARATOR
Intervention: Exercise-Attention Control (EAC) group
Number of subjects: 141
Study 23522927 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL) group
Number of subjects: 141
Study 20716319 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (90% short‐chain galacto‐oligosaccharides, 10% long‐chain fructo‐oligosaccharides: Immunofortis(®) and Bifidobacterium breve M‐16V)
Number of subjects: 29
Study 20716319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 19807821 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD)
Number of subjects: 16
Study 19807821 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 16
Study 19807821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (OFD and GTR)
Number of subjects: 16
Study 16977442 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 ml contrast material at 2.0 ml/s
Number of subjects: 120
Study 16977442 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 ml contrast material followed by 40 ml saline at 2.0 ml/s
Number of subjects: 120
Study 16977442 — intervention group
Group type: COMPARATOR
Intervention: 60 ml contrast material at 1.5 ml/s
Number of subjects: 120
Study 16977442 — intervention group
Group type: COMPARATOR
Intervention: 60 ml contrast material followed by 30 ml saline at 1.5 ml/s
Number of subjects: 120
Study 16977442 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline chaser (40 ml or 30 ml)
Number of subjects: 120
Study 15074087 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuesaitong injection (XSTI)
Number of subjects: 87
Study 15074087 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 87
Study 11190987 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline chloride (2 g) added to usual TPN regimen
Number of subjects: 11
Study 11190987 — intervention group
Group type: COMPARATOR
Intervention: Usual TPN regimen (Control)
Number of subjects: 11
Study 9613534 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL 0.9% saline injected into the epidural catheter
Number of subjects: 20
Study 9613534 — intervention group
Group type: COMPARATOR
Intervention: 1 mL 0.9% saline injected into the epidural catheter
Number of subjects: 20
Study 8578840 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib vaccine mixed with whole‐cell DTP vaccine
Number of subjects: 0
Study 8578840 — intervention group
Group type: COMPARATOR
Intervention: Hib vaccine administered in separate limbs from whole‐cell DTP vaccine
Number of subjects: 0
Study 2517007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (RIL) 1 mg every morning or 1 mg twice daily if necessary
Number of subjects: 157
Study 2517007 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (MD) 250 mg morning and evening or 500 mg twice daily if necessary
Number of subjects: 157
Study 326378 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic screening with clinical examination and mammography
Number of subjects: 128
Study 326378 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 128
Study 326378 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program
Number of subjects: 128
Study 326378 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 128
Study 326378 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening under 50 years of age
Number of subjects: 128
Study 29602709 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive fixation device
Number of subjects: 100
Study 29602709 — intervention group
Group type: COMPARATOR
Intervention: Suture fixation
Number of subjects: 100
Study 29602709 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff recommendation
Number of subjects: 100
Study 27684085 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL LMWF-5A
Number of subjects: 40
Study 27684085 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (saline)
Number of subjects: 40
Study 26849537 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames (EG) using the Xbox Kinect™ device
Number of subjects: 100
Study 26849537 — intervention group
Group type: COMPARATOR
Intervention: Home Exercise (HE)
Number of subjects: 100
Study 23221493 — intervention group
Group type: EXPERIMENTAL
Intervention: Comments to the 'Black' magazine
Number of subjects: 32